Latest Schedule 13G passive stakes

NASDAQ
BeyondSpring Inc. has filed an amendment to its Schedule 13G, detailing changes in beneficial ownership among key reporting persons.
NASDAQ
Clear Street LLC has reported beneficial ownership of 308,923 shares, representing 5.0% of the common stock of StoneBridge Acquisition II Corporation as of June 30, 2026.
NASDAQ
An amendment to Schedule 13G has been filed for CoreWeave, Inc., detailing updated beneficial ownership percentages for key individuals and trusts as of June 30, 2026.
NASDAQ
Kamal Seyed Ghaffarian and X-Energy Holdings, LLC report significant beneficial ownership stakes in X-Energy, Inc. Class A Common Stock as of June 30, 2026.
NASDAQ
Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.19% of ICU Medical, Inc.'s common stock as of June 30, 2026.
NYSE
Fuller & Thaler Asset Management, Inc. has reported beneficial ownership of 5.14% of Maximus, Inc.'s common stock as of June 30, 2026.
NYSE
Fuller & Thaler Asset Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.94% of Greif, Inc. common stock as of June 30, 2026.
NYSE
Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 20,880,498.21 shares, representing 7.06% of the common stock of Graphic Packaging Holding Co.
NASDAQ
OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Forte Biosciences, Inc. common stock.
NYSE
Fuller & Thaler Asset Management, Inc. has filed an amendment to its Schedule 13G, reporting a minor beneficial ownership of Primoris Services Corp common stock.
NYSE
Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 16,708,253.67 shares, representing 4.69% of FNB Corp/PA's common stock, as of June 30, 2026.
NASDAQ
Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.03% in Collegium Pharmaceutical, Inc. common stock as of June 30, 2026.
Fuller & Thaler Asset Management, Inc. has reported an increased beneficial ownership of Beacon Financial Corp. common stock, now holding 4.7% of the class.
NASDAQ
Corsair Capital and affiliated entities have reported beneficial ownership of 3.9% of Cineverse Corp.'s Class A Common Stock as of June 30, 2026.
NASDAQ
Perceptive Advisors LLC, along with affiliated entities, has reported a beneficial ownership of 4.9% in Spyre Therapeutics, Inc., holding 4,319,496 shares.
NASDAQ
Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 6.99% in Science Applications International Corp. as of June 30, 2026.
Berto Acquisition Corp. II files Schedule 13G detailing significant beneficial ownership stakes held by Berto Acquisition Sponsor II LLC, Harry L. You, and Robert You.
NASDAQ
NewHold Industrial Technology IV, LLC, along with managing members Kevin Charlton and Samy Hammad, have filed a Schedule 13G detailing their beneficial ownership of NewHold Investment Corp IV.
NASDAQ
Decagon Asset Management LLP and Benjamin John Durham have reported beneficial ownership of 5.52% of Oaktree Acquisition Corp. III Life Sciences' Class A ordinary shares.
NYSE
H/2 Credit Manager LP and H/2 Credit Manager GP LLC have filed an amended Schedule 13G, reporting 0.00 shares of Veris Residential, Inc. common stock beneficially owned.
Zippy, Inc. has disclosed beneficial ownership of 571,427 shares, representing 4.3% of Forum Markets Inc.'s common stock, as of April 20, 2026.
NASDAQ
ADAR1 Capital Management, LLC, along with related entities and individuals, has filed a Schedule 13G amendment indicating a reduction in their beneficial ownership of Ovid Therapeutics Inc. common stock to below 5%.
NASDAQ
Novo Holdings A/S has reported beneficial ownership of 9.0% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.
NASDAQ
Fund 1 Investments, LLC has reported beneficial ownership of 3,553,230 shares, representing 9.6% of the Class A Common Stock of 1-800 Flowers Com Inc.
NASDAQ
Novo Holdings A/S has reported beneficial ownership of 3,883,289 shares, representing 8.8% of Avalyn Pharma Inc.'s common stock.
NASDAQ
CastleKnight Master Fund LP and affiliated entities have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Innventure, Inc. common stock.
NYSE
Fund 1 Investments, LLC has reported acquiring a 5.49% stake in Genesco Inc., holding 609,963 shares of common stock.
NYSE
Two Seas Capital LP, along with its general partner and chief investment officer, has disclosed a beneficial ownership of 8,377,636 shares, representing 5.4% of Sable Offshore Corp.'s common stock as of June 30, 2026.
NASDAQ
Greenoaks LLC, along with its managing partners Neil Mehta and Benjamin Peretz, has reported beneficial ownership of 1,010,000 shares of Navan, Inc. Class A Common Stock, representing 0.42% of the class.
NASDAQ
ADAR1 Capital Management, along with affiliates, has reported beneficial ownership of 9.9% of Grace Therapeutics, Inc. common stock, primarily through warrants.